Logo

Gates Foundation Supports Fast Track Development of Proteome Systems TB Diagnostic

Jun 21, 2005

NEW YORK, June 21 (GenomeWeb News) - The Foundation for Innovative New Diagnostics, which is funded by the Bill & Melinda Gates Foundation, said that it has signed a letter of intent with Australian biotech Proteome Systems to "fast track" the development of a rapid antigen-based diagnostic test for active tuberculosis.

 

FIND announced the collaboration today at BIO 2005 in Philadelphia.

 

Proteome Systems' test is expected to detect TB antigens indicating active TB infection in the human body. The test will also monitor disease progression and response to treatment in TB patients regardless of the immune status of the host, FIND said.

 

Stephen Porges, Proteome Systems' CEO, said that the partnership with FIND "will provide the critical support to speed the development of the test in addition to clinical material, assistance with clinical trials and fast tracking of registration, in return for exclusive royalty-free rights to distribute the product in the public health sector in developing countries."

Breaking News
The Scan

Expanded Genetic Testing Uncovers Hereditary Cancer Risk in Significant Subset of Cancer Patients

In Genome Medicine, researchers found pathogenic or likely pathogenic hereditary cancer risk variants in close to 17 percent of the 17,523 patients profiled with expanded germline genetic testing.

Mitochondrial Replacement Therapy Embryos Appear Largely Normal in Single-Cell 'Omics Analyses

Embryos produced with spindle transfer-based mitochondrial replacement had delayed demethylation, but typical aneuploidy and transcriptome features in a PLOS Biology study.

Cancer Patients Report Quality of Life Benefits for Immune Checkpoint Inhibitors

Immune checkpoint inhibitor immunotherapy was linked in JAMA Network Open to enhanced quality of life compared to other treatment types in cancer patients.

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.